Effects of Chemotherapy on Perceived Daily Performance and Executive Functions of Adults With Cancer

NCT ID: NCT05599698

Last Updated: 2024-05-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-15

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine changes in perceived daily performance and executive functioning following chemotherapy in individuals with non-central nervous system cancers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

chemotherapy

chemotherapy

Group Type EXPERIMENTAL

Chemotherapy

Intervention Type OTHER

Standard chemotherapy protocols for adjuvant \& neoadjuvant treatment for different types of solid malignancies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chemotherapy

Standard chemotherapy protocols for adjuvant \& neoadjuvant treatment for different types of solid malignancies

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed with a primary non-central nervous system malignancy (lung, breast, colon, ulcer, urinary tract, canine tumors).
* Stages I-III.
* Pre-commencement of adjuvant (post-surgery) or neoadjuvant (prior to surgery) chemotherapy.
* Understand and read Hebrew.
* Have at least 12 years of education.

Exclusion Criteria

* Diagnosed with central nervous system malignancies.
* Had a previous malignancy.
* Have or had metastatic disease.
* Have a history of a neurological condition or severe depression.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tel Aviv University

OTHER

Sponsor Role collaborator

Bnai Zion Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

abed.agbarya

Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Abed Agbarya, MD

Role: PRINCIPAL_INVESTIGATOR

[email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bnai Zion Medical Center

Haifa, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

khawla loubani, PhD

Role: CONTACT

+97240504564402

Abed Agbarya, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Abed Agbarya, MD

Role: primary

+972502062679

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0106-22-BNZ

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.